直径<2cm小肾肿物治疗方式与死亡率的时序趋势
基于SEER数据库2004-2022年20769例<2cm小肾肿物患者,分析非干预管理(NIM)、局部肿瘤消融(LTD)、肾部分切除(PN)和根治性肾切除(RN)的时序趋势及5年癌症特异性死亡率(CSM)。NIM率从2004年8.0%升至2022年23.9%(EAPC+5.1%,p<0.001),老年和非洲裔患者增幅更显著;5年CSM稳定在2.8%-2.9%(EAPC-1.0%,p=0.4)。
要点
- NIM率从2004年8.0%升至2022年23.9%,EAPC+5.1%(p<0.001)。
- 年龄≥70岁(OR 9.24)和非洲裔(OR 1.39)独立预测NIM。
- 5年CSM稳定在2.8%-2.9%,EAPC-1.0%(p=0.4)。
核心结论
- 在<2cm小肾肿物患者中,NIM率虽总体仍低,但随时间显著增加,且未伴随5年CSM升高。
研究设计与样本
- 基于SEER数据库(2004-2022)的回顾性队列研究,纳入20769例<2cm小肾肿物患者,按四种管理方式分层。
主要发现
- PN占58.3%(12107例),NIM占17.1%(3558例),RN占13.9%(2879例),LTD占10.7%(2225例)。
- NIM率从2004年8.0%升至2022年23.9%(EAPC+5.1%,p<0.001)。
- 年龄≥70岁患者NIM率从22.0%升至45.9%(∆+23.9,EAPC+3.3%,p<0.001)。
- 非洲裔患者NIM率从4.5%升至23.2%(∆+18.7,EAPC+5.0%,p<0.001)。
- 5年CSM在2004年为2.8%,2017年为2.9%(EAPC-1.0%,p=0.4)。
关键数值与推荐
- 多变量logistic回归显示年龄≥70岁(OR 9.24,p<0.001)和非洲裔(OR 1.39,p<0.001)独立预测NIM。
临床怎么用
- 对于<2cm小肾肿物,尤其老年和非洲裔患者,可考虑更广泛地采用NIM,因NIM增加未伴随CSM升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore contemporary rates and temporal trends of Guidelines-recommended management options for small renal masses (SRM)<2cm, that include non-interventional management (NIM), local tumor destruction (LTD) and nephrectomy (either partial -PN- or radical -RN). METHODS: Within the SEER database (2004-2022), SRM<2cm patients were identified and stratified according to four examined management options. Estimated annual percentage change (EAPC) were tabulated according to management type. Five-years cancer-specific mortality (CSM) rates were computed. Multivariable logistic regression tested predictors of NIM, LTD and RN. RESULTS: Of 20,769 SRM<2cm patients, 12,107 (58.3%) underwent PN vs. 3,558 (17.1%) NIM vs. 2,879 (13.9%) RN vs. 2,225 (10.7%) LTD. During the study span, NIM rates increased from 8.0% in 2004 to 23.9% in 2022 (EAPC+5.1%, p<0.001). The increase in NIM rates was more pronounced in patients aged ≥70 years (from 22.0% to 45.9%, ∆+23.9, EAPC +3.3%, p<0.001). and in African American (from 4.5% to 23.2%, ∆+18.7, EAPC +5.0%, p<0.001). At multivariable logistic regression models age ≥70 years (OR 9.24, p<0.001) and African American race (OR 1.39, p<0.001) independently predicted NIM. Five-years CSM remained stable over the study span: 2.8% in 2004 and 2.9% in 2017 (EAPC -1.0%, p=0.4). CONCLUSION: In SRM<2cm patients, rates of NIM are very low, even in the most recent study years. However, NIM rates increased overtime across all sex, age and race categories, with most pronounced increase among elderly and African American. Concurrently, five-years CSM rates have not increased despite the wider adoption of NIM.
引用
- Nicolazzini M, Catanzaro C, Polverino F, et al. Temporal trends of treatment and mortality in small renal masses <2cm. Urology. 2026. PMID: 42925960. doi:10.1016/j.urology.2026.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。